SCHEDULE: Lynx1 Capital Offers to Acquire Neuphoria IP Assets

Lynx1 Capital Management LP and Weston Nichols, holding a 16.3% stake in Neuphoria Therapeutics, have made an all-cash or stock offer to acquire certain intellectual property assets from the company.

Summary

• Lynx1 Capital Management LP and Weston Nichols (Reporting Persons) beneficially own 875,328 shares of Neuphoria Therapeutics Inc. Common Stock, representing 16.3% of the outstanding shares.
• This percentage is based on 5,377,329 shares outstanding as of November 13, 2025, as reported in the Company's quarterly report on Form 10-Q.
• On December 26, 2025, the Reporting Persons made an offer to Neuphoria Therapeutics Inc.'s Board to acquire certain intellectual-property-related assets.
• The offer proposes an all-cash transaction or, if preferred by the company, delivery of Neuphoria Therapeutics Inc. Common Stock with equivalent value.
• The IP Rights Proposal is subject to the Reporting Persons' due diligence and agreement on definitive documentation.
• There is no obligation for either party to complete the transaction, and there is no assurance regarding the outcome of discussions or the terms of any potential agreement.

Sentiment

Score: 6

Explanation: The filing indicates a significant shareholder's active interest in Neuphoria Therapeutics' assets, which could be positive for valuation. However, the non-binding nature and uncertainty surrounding the transaction's completion or terms introduce a degree of caution.

Positives

• An unsolicited offer for intellectual property assets could indicate a potential valuation floor or strategic interest in Neuphoria Therapeutics' technology.
• The offer provides an opportunity for Neuphoria Therapeutics to potentially monetize non-core or underutilized assets, which could improve liquidity or focus.
• The proposal includes an all-cash option, which could provide immediate capital to the company.

Negatives

• The offer is non-binding and subject to due diligence and definitive documentation, meaning there is no guarantee a transaction will occur.
• The Reporting Persons explicitly state they are not obligated to complete a transaction, and terms may differ, creating uncertainty for shareholders.
• The potential disposition of material assets could alter the company's strategic direction or asset base significantly.

Risks

• Uncertainty regarding the outcome of discussions related to the IP Rights Proposal.
• Risk that no agreement will be reached between Neuphoria Therapeutics Inc. and the Reporting Persons.
• Potential for the terms of any transaction to differ significantly from those initially contemplated by the IP Rights Proposal.
• The Reporting Persons may make offers for other assets of the company, leading to further strategic shifts.
• The IP Rights Proposal may result in the disposition of company securities or a sale/transfer of a material amount of the company's assets, which could impact future operations and valuation.

Future Outlook

The Reporting Persons have made a non-binding offer to acquire intellectual property assets from Neuphoria Therapeutics Inc., which could lead to a significant transaction involving either cash or an exchange of company stock. However, there is no assurance that any agreement will be reached or that the terms will not differ from the initial proposal. The Reporting Persons may also pursue other strategic actions or offers for additional company assets.

Industry Context

This event reflects a potential strategic move within the biotechnology or pharmaceutical sector, where intellectual property is a critical asset. Such offers can indicate a belief in the underlying value of a company's R&D pipeline or patented technologies, potentially signaling consolidation or asset divestiture trends in the industry.

Comparison to Industry Standards

• The 16.3% stake held by Lynx1 Capital Management LP and Weston Nichols is a significant minority position, often indicative of an activist investor or a strategic long-term holder seeking influence. This level of ownership is substantial enough to warrant a Schedule 13D filing and provides a platform for engaging with management on strategic matters, similar to activist campaigns seen with companies like Starboard Value's involvement in various tech and consumer firms or Carl Icahn's stakes in energy companies.
• Offers to acquire specific intellectual property assets are common in the biotech and pharmaceutical industries, where R&D pipelines and patents are key value drivers. For example, larger pharmaceutical companies frequently acquire specific drug candidates or technology platforms from smaller biotech firms (e.g., Pfizer acquiring Seagen for its ADC technology, or AbbVie acquiring Allergan for its neuroscience and aesthetics portfolio). The structure of the offer (cash or stock) is also standard in such transactions, providing flexibility to the target company.
• The non-binding nature and conditions (due diligence, definitive documentation) are standard practice for initial proposals of this magnitude, mirroring the early stages of M&A discussions across industries.

Stakeholder Impact

• Shareholders: Potential for increased share price if the IP acquisition proceeds at a favorable valuation, or uncertainty if the deal falls through. Could lead to a strategic shift impacting long-term value.
• Employees: Potential impact on employees associated with the intellectual property assets being considered for sale.
• Customers/Partners: Potential impact on future product development or partnerships if key IP assets are divested.

Next Steps

• Neuphoria Therapeutics Inc.'s Board will consider the IP Rights Proposal.
• Discussions between the Reporting Persons and Neuphoria Therapeutics Inc. regarding the proposal.
• Reporting Persons' due diligence on the intellectual property assets.
• Negotiation and agreement on definitive documentation for the acquisition, if the parties proceed.
• Potential for Reporting Persons to make offers for other assets of the company.
• Potential for Reporting Persons to pursue other plans or proposals with company management, the Board, or other stockholders.

Key Dates

Recommendation

The filing reveals a significant shareholder's offer to acquire key intellectual property, which could unlock value for Neuphoria Therapeutics. However, the offer is non-binding and subject to substantial conditions, creating significant uncertainty regarding its completion and terms. While the offer itself suggests potential underlying value, the lack of a definitive agreement and the possibility of the deal falling through or changing significantly warrant a 'hold' recommendation. Investors should await further clarity on the negotiations and the potential impact on the company's strategic direction and financial health before making a definitive 'buy' or 'sell' decision.

Keywords

Neuphoria Therapeutics, Lynx1 Capital Management, Weston Nichols, Schedule 13D/A, Intellectual Property Acquisition, Asset Sale, Beneficial Ownership, Biotechnology, Pharmaceuticals, M&A Offer